Retatrutide

Name: Retatrutide - Artemis Labs
Availability: InStock

Price range: $70.00 through $240.00

Tirzepatide engages two gut-hormone receptors. Retatrutide engages three — it adds glucagon, which nudges the body toward spending energy rather than only toward eating less. That is the idea under test: pair the appetite side with a thermogenic side and see whether the two add up.

Continue readingShow less

The trial record. A Phase 2 obesity trial (Jastreboff 2023, PMID 37366315) and a parallel Phase 2 diabetes trial (Rosenstock 2023, PMID 37385280) are published in peer-reviewed form; Phase 3 TRIUMPH figures circulating in headlines are sponsor topline announcements, not peer-reviewed publications. The reported results live in the linked papers, not on this page.

Where it actually stands. Retatrutide remains investigational. The Phase 3 outcome data has not been published in a peer-reviewed journal, so that headline is a company topline rather than a reviewed result. It sits roughly two percentage points ahead of tirzepatide on comparable Phase 2 endpoints — a gap that has not yet been confirmed in print.

Lyophilized triple-agonist peptide.

Vial Size

Clear

Volume pricingApplied automatically at checkout

Quantity	Per unit	You save
3–4 units	$109.20	−9%
5–9 units	$104.40	−13%
10+ units	$98.40	−18%

Free shipping on orders over $300

Pay by Venmo or Cash App — instructions are emailed with your order.

5 published sources cited on this page see them

For research use only. Not for human consumption.

SKU: N/A Category: Metabolic Research Tags: glp1-gip-glucagon, phase-3, research peptide, retatrutide, triple-agonist, TRIUMPH-trials Research areas: Glucose Metabolism & Insulin Signaling · Metabolic & Incretin Signaling

Description

Retatrutide is a lab-made peptide. It binds three targets at once: GLP-1, GIP, and glucagon. Tirzepatide, the closest studied peptide, binds just the first two. Artemis Labs supplies retatrutide as a dry powder for lab research.

Reviewed August 21, 2026 · Artemis Labs

What is retatrutide?

Retatrutide is studied in laboratory research as a triple-agonist research peptide — it activates the GLP-1, GIP, and glucagon receptors. This extends the dual-agonist (tirzepatide) class by adding glucagon-receptor activity, which is studied in laboratory models of energy expenditure and brown-adipose-tissue thermogenesis.

What did the published Phase 2 trial report?

The Phase 2 obesity trial (Jastreboff et al., New England Journal of Medicine 2023, PMID 37366315) randomized adults with obesity to one of four retatrutide dose arms or placebo over 48 weeks. The primary endpoint was percent change in body weight; the reported effect sizes are in the paper, not reproduced here. Adverse-event profile aligned with the GI-tolerability findings reported across the incretin-agonist class.

Has peer-reviewed Phase 3 evidence been published?

One peer-reviewed Phase 3 outcome paper has published: TRANSCEND-T2D-1, in type 2 diabetes, in The Lancet on June 13, 2026 (PMID 42250575; registered NCT06354660). No peer-reviewed Phase 3 outcome paper in obesity has published. The TRIUMPH design paper appeared in Diabetes, Obesity and Metabolism in January 2026 (PMID 41090431). The sponsor has released topline announcements for TRIUMPH-1 (obesity without diabetes; 2,339 participants) and for TRIUMPH-4 (December 2025). Topline figures are sponsor announcements, not peer-reviewed outcomes; this page will cite the trial publications when they appear.

What is retatrutide used for in laboratory research?

Researchers investigating the triple-receptor mechanism, comparative incretin-agonist class research, or laboratory models of glucagon-receptor-mediated energy expenditure may evaluate retatrutide alongside tirzepatide (dual-agonist comparator) and semaglutide (GLP-1-only comparator). For research use only. Not for human consumption. These statements have not been evaluated by the FDA.

What are the limits of the current retatrutide evidence?

No peer-reviewed Phase 3 outcomes in obesity. The TRIUMPH figures above are sponsor topline announcements, not peer-reviewed results. The one peer-reviewed Phase 3 outcome paper is TRANSCEND-T2D-1 in type 2 diabetes (PMID 42250575); in the TRIUMPH obesity programme the only publication to date is the trial-design paper (PMID 41090431).
The pivotal evidence is a single Phase 2 trial. The 48-week Jastreboff trial (PMID 37366315) is the one peer-reviewed outcome dataset in obesity; no head-to-head peer-reviewed comparison against another incretin agonist has been published.
Tolerability. The Phase 2 adverse-event profile aligned with the gastrointestinal-tolerability findings reported across the incretin-agonist class.
Identity data are incomplete in the public record. No CAS Registry Number, molecular weight or full published sequence for retatrutide is established in this record; the compound is referred to by its INN.

Analytical Specifications

Common name	Retatrutide
Class	Triple GLP-1 / GIP / glucagon receptor agonist (incretin tri-agonist)
Structural modification	C18 fatty-diacid moiety; binds serum albumin reversibly
Reported circulating half-life	~6 days; pharmacokinetics dose-proportional across the studied range (Jastreboff et al., NEJM 2023, PMID 37366315)
Sequence / molecular weight / CAS number	Not established in this record
Vial contents	10 mg, 15 mg, 20 mg or 30 mg per vial

References

Jastreboff AM, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine 389(6):514–526. PMID 37366315 · DOI 10.1056/NEJMoa2301972
TRIUMPH-4 trial-design paper (2026). Diabetes, Obesity and Metabolism, January 2026. PMID 41090431

Additional information

Vial Size	10mg, 15mg, 20mg, 30mg, 60mg, 50mg, 40mg, 36mg, 24mg, 5mg

Science & Research

Which receptors does retatrutide bind?

GLP-1 Receptor: Retatrutide acts as a GLP-1 receptor agonist; in laboratory models, GLP-1R activation is associated with delayed gastric emptying and effects on appetite-regulatory hypothalamic pathways.

GIP Receptor: Retatrutide also activates the GIP receptor; GIP-receptor pharmacology has been studied in laboratory models of insulin secretion and hypothalamic appetite signaling.

Glucagon Receptor: The third receptor target. Glucagon-receptor activation has been studied in laboratory models of brown-adipose-tissue thermogenesis (UCP1 activation) and white-adipose-tissue lipolysis. In the triple-agonist context, the glucagon arm’s hyperglycemic potential is offset by concurrent GLP-1 / GIP activity in research models.

What pharmacokinetics have been published for retatrutide?

Retatrutide carries a C18 fatty-diacid moiety that binds reversibly to serum albumin, extending the circulating half-life to approximately 6 days. Pharmacokinetics are dose-proportional across the studied range (Jastreboff et al., NEJM 2023, PMID 37366315).

What did the published Phase 2 trial report?

Jastreboff AM et al. (2023): Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine 389(6):514–526. PMID 37366315 · DOI 10.1056/NEJMoa2301972 Randomized adults with obesity to one of four retatrutide dose arms or placebo over 48 weeks; the primary endpoint was percent change in body weight. Reported results are in the paper, not reproduced here.

Has peer-reviewed Phase 3 evidence been published?

Peer-reviewed Phase 3 outcome data for retatrutide have not yet been published. The TRIUMPH design paper is Diabetes, Obesity and Metabolism, January 2026, PMID 41090431. The sponsor has released topline announcements for TRIUMPH-1 (obesity without diabetes; 2,339 participants) and for TRIUMPH-4 (December 2025). Topline figures are sponsor announcements, not peer-reviewed outcomes; this section will cite the trial publications when they appear.

References

Note: Three PMIDs previously listed in this section (34889371, 39046181, 38650651) were determined to be fabricated or misattributed during the 2026-05-20 catalog audit and have been removed.